ATE455793T1 - Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen - Google Patents

Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Info

Publication number
ATE455793T1
ATE455793T1 AT02721722T AT02721722T ATE455793T1 AT E455793 T1 ATE455793 T1 AT E455793T1 AT 02721722 T AT02721722 T AT 02721722T AT 02721722 T AT02721722 T AT 02721722T AT E455793 T1 ATE455793 T1 AT E455793T1
Authority
AT
Austria
Prior art keywords
meningococcal
epitopes
monoclonal antibodies
molecular mimetics
antibodies against
Prior art date
Application number
AT02721722T
Other languages
German (de)
English (en)
Inventor
Dan Granoff
Gregory Moe
Rino Rappuoli
Original Assignee
Novartis Vaccines & Diagnostic
Childrens Hosp Oak Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic, Childrens Hosp Oak Res Inst filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE455793T1 publication Critical patent/ATE455793T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02721722T 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen ATE455793T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28455401P 2001-04-17 2001-04-17
US32683801P 2001-10-03 2001-10-03
PCT/US2002/011501 WO2002083711A2 (en) 2001-04-17 2002-04-11 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies

Publications (1)

Publication Number Publication Date
ATE455793T1 true ATE455793T1 (de) 2010-02-15

Family

ID=26962673

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721722T ATE455793T1 (de) 2001-04-17 2002-04-11 Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen

Country Status (10)

Country Link
US (1) US7534444B2 (enExample)
EP (1) EP1379272B1 (enExample)
JP (3) JP2004529643A (enExample)
CN (1) CN1306956C (enExample)
AT (1) ATE455793T1 (enExample)
AU (1) AU2002252638A1 (enExample)
CA (1) CA2439428C (enExample)
DE (1) DE60235155D1 (enExample)
RU (1) RU2322451C2 (enExample)
WO (1) WO2002083711A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2457100A (en) * 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1179072A2 (en) 1999-05-19 2002-02-13 Chiron S.P.A. Combination neisserial compositions
WO2001051500A1 (en) 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2000278267A1 (en) 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US7354909B2 (en) 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2002366710A1 (en) 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8263091B2 (en) * 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
WO2005023295A2 (en) * 2003-09-10 2005-03-17 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
CN1918176A (zh) * 2004-02-18 2007-02-21 默克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
DE102004023906A1 (de) * 2004-05-13 2005-12-22 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Verfahren zur Herstellung von chemischen Mikroarrays
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
DE112009000608B4 (de) 2008-04-18 2017-12-28 Denso Corporation Kälteerzeugungszyklusvorrichtung eines Ejektor-Typs
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체
WO2013132040A2 (en) * 2012-03-08 2013-09-12 Novartis Ag In vitro potency assay for protein-based meningococcal vaccines
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20190049940A (ko) 2015-02-19 2019-05-09 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
DE3483957D1 (de) 1983-11-21 1991-02-21 Wellcome Found Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen.
US4727136A (en) 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4970070A (en) 1986-02-07 1990-11-13 Genetic Systems Corporation Protective monoclonal antibody compositions for infections due to group B streptococcus
JPH01125328A (ja) * 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
US5128460A (en) * 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SU1708846A1 (ru) * 1989-11-22 1992-01-30 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Штамм бактерий NeISSeRIa меNINGIтIDIS серогруппы В - продуцент капсульного полисахарида и полисахаридно-белкового комплекса
RO111416B1 (ro) * 1989-12-14 1996-10-31 Ca Nat Research Council Polizaharide modificate de neisseria meningitidis si e coli, combinatii antigenice si metoda de imunizare
RU2068270C1 (ru) * 1993-01-13 1996-10-27 Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова Антиген менингококков группы в
US5510264A (en) * 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
GB9422096D0 (en) 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
DE69708318T3 (de) 1996-08-27 2006-11-16 Novartis Vaccines and Diagnostics, Inc., Emeryville Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
DE69840508D1 (de) 1997-08-27 2009-03-12 Childrens Hosp Medical Center Molekular-mimetika von meningokokkus b epitopen
MX343752B (es) * 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
AU2457100A (en) 1999-02-26 2000-09-14 Chiron S.P.A. Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
ES2323845T3 (es) * 1999-04-30 2009-07-27 Novartis Vaccines And Diagnostics, Inc. Secuencias genomicas de neisseria y procedimientos de uso.
PT2270030E (pt) * 2000-02-28 2012-07-24 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria

Also Published As

Publication number Publication date
US7534444B2 (en) 2009-05-19
US20040013686A1 (en) 2004-01-22
RU2322451C2 (ru) 2008-04-20
AU2002252638A1 (en) 2002-10-28
DE60235155D1 (de) 2010-03-11
RU2003133300A (ru) 2005-04-20
WO2002083711A3 (en) 2003-11-06
EP1379272B1 (en) 2010-01-20
CA2439428A1 (en) 2002-10-24
EP1379272A4 (en) 2005-12-14
JP2010011868A (ja) 2010-01-21
WO2002083711A2 (en) 2002-10-24
JP2008259503A (ja) 2008-10-30
JP5215275B2 (ja) 2013-06-19
JP2004529643A (ja) 2004-09-30
CA2439428C (en) 2012-01-24
CN1306956C (zh) 2007-03-28
CN1602204A (zh) 2005-03-30
EP1379272A2 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
DE60235155D1 (de) Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
EP2277537A3 (en) Neisseria meningitidis conjugate combination vaccine
DK1007546T3 (da) Molekylære mimetika af meningokok-B-epitoper
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
JP2007533729A5 (enExample)
CY1109202T1 (el) Συνθεσεις που περιεχουν αντιγονα απο τους οροτυπους b και c της neisseria meningitidis οπως και επιπλεον αντιγονα απο τον οροτυπο α
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
MXPA05009351A (es) Conjugados de polisacarido-proteina portadora adhesina superficial de estafilococo para inmunizacion contra infecciones nosocomiales.
BR9906927A (pt) Proteìnas de neisseria meningitidis
FR17C1042I2 (fr) Nouvelles compositions immunogenes pour la prevention et le traitement de la meningite a meningocoques
BR9813930A (pt) antìgeno neisserial
ATE302411T1 (de) Diagnose, prophylaxe und behandlung von morbus crohn durch die verwendung des ompc antigens
BR0012424A (pt) Peptìdeos meningocócicos antigênicos
Plested et al. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B
MA29459B1 (fr) Vaccins
NO902280L (no) Ny poroes farmasoeytisk form og fremstilling derav.
BRPI0500090A (pt) Composição de acabamento
TR200003467T2 (tr) Neisseria meningitidis antijenik polipeptidler, mütekabil polinükleotidler ve koruyucu antikorlar
DK1560594T3 (da) Antigeniske sammensætninger til immunisering af ikke-menneskelige pattedyr mod Streptococcus equi
EP2364726A3 (en) Vaccine against neisseria infection
FI955916A0 (fi) N-((1-(4-(4-fluorifenoksi)butyyli)-4-piperidinyyli)-N-metyyliamino)-2-bentsotiatsololeja luokan III rytmihäiriölääkkeinä
Luijkx et al. Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form
NO20006087L (no) Fremgangsmåter for å öke nivåer av acetylcholin
MX2024014807A (es) Composicion inmunogenica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties